Sunday, January 8, 2017

Biopharmaceutical M&A expected to soar in 2017 as pricing pressures dim global revenue outlook

The EY report finds the industry's need to engage in M&A has become amplified as payers continue to push back forcefully on price increases for older ...

more here

No comments:

Post a Comment